Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ASH 2018 | Waldenström’s macroglobulinemia highlights from ASH 2018

Jonas Paludo • 4 Dec 2018
ASH 2018
Lymphoma Non-Hodgkin Lymphoma Rare Diseases Waldenström’s Macroglobulinemia Ibrutinib Venetoclax

Jonas Paludo, MD, of the Mayo Clinic, Rochester, MN, shares his view on the highlights for Waldenström’s macroglobulinemia from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.

More from Jonas Paludo

Managing CAR-T therapy-related AEs & treatment options for patients who progress after CAR-T therapy 2:36
Managing CAR-T therapy-related AEs & treatment options for patients who progress after CAR-T therapy
Jonas Paludo • 28 Oct 2022
The importance of studying RNA expression in rare diseases such as WM 0:57
The importance of studying RNA expression in rare diseases such as WM
Jonas Paludo • 28 Oct 2022
Long non-coding RNA expression in IgM-MGUS and Waldenström’s macroglobulinemia 1:50
Long non-coding RNA expression in IgM-MGUS and Waldenström’s macroglobulinemia
Jonas Paludo • 28 Oct 2022
2:15
Association between depth of response and survival in Waldenström’s
Jonas Paludo • 6 Dec 2018

Related Videos

Long-term follow-up results from ELM-2: odronextamab in R/R FL 8:08
Long-term follow-up results from ELM-2: odronextamab in R/R FL
Gottfried von Keudell • 18 Sep 2025
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL 1:24
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL
Tycel Phillips • 5 Sep 2025
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute 1:01
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute
Krish Patel • 4 Sep 2025
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations 1:52
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations
Tycel Phillips • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals